BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Kadmon Corporation (Formerly Known As Kadmon Pharmaceuticals) 

Alexandria Center for Life Sciences
450 East 29th Street, 5th Floor
New York  New York  10016  U.S.A.
Phone: 212-308-6000 Fax: n/a


SEARCH JOBS




Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Kadmon Corporation Presents Preclinical Data On Bi-Functional Anti-PD-L1/IL-15 Fusion Protein At EORTC-NCI-AACR Symposium 11/19/2014 1:00:57 PM
Kadmon Corporation Researchers Define Importance Of ROCK2 Signaling Pathway In Human Autoimmune Response 11/11/2014 10:56:04 AM
Convicted ImClone Systems (LLY) Boss Becomes Chief Of Innovation At Kadmon Corporation While Brother Harlan W. Waksal, M.D Takes CEO Post 9/24/2014 8:16:08 PM
Kadmon Corporation Initiates Phase 2a Portion Of KD020 Study In Autosomal Dominant Polycystic Kidney Disease 6/19/2014 11:41:08 AM
Kadmon Corporation Announces National Institutes of Health (NIH) Agreement To Evaluate Gene Therapy Program 6/16/2014 11:08:38 AM
Kadmon Corporation Announces The Initiation Of A Phase 1b/2a Study Of KD019 And Trastuzumab In HER2-Positive Metastatic Breast Cancer 6/4/2014 9:03:53 AM
Kadmon Corporation To Present At Jefferies and Co. 2014 Global Healthcare Conference 5/30/2014 9:35:00 AM
Kadmon Corporation Presents Results Of KD025 Preclinical And Clinical Studies At AAI Annual Meeting 5/5/2014 10:06:19 AM
Kadmon Corporation Announces The Initiation Of KD025 Phase 2 Program In Psoriasis 4/8/2014 10:32:36 AM
Kadmon Corporation Presents Preclinical Results Demonstrating KD019 Activity In Trastuzumab Resistant HER2+ Breast Cancer 4/8/2014 10:26:44 AM
12